The study population was retrospectively selected from a database of patients with FL, referred to our Institute between January 2011 and May 2019, with a post-treatment follow-up of at least 30 months. The sample included 79 patients with newly diagnosed FL grades 1–3A according to the 2016 WHO classification, treated with first-line chemotherapy regimens R-CHOP-like or R-B. Patients who relapsed within 30 months were also included in the analysis.
Patient inclusion criteria included an age range of 60–80 years, a baseline 18FDG PET/CT scan suitable for radiomic analysis performed at the Department of Diagnostic Imaging Radiology of the Policlinico Tor Vergata, first-line treatment with six cycles R-CHOP: Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 (liposomal Doxorubicin 50 mg/m2 in R-COMP), Vincristine 1.4 mg/m2(for a maximum of 2 mg total dose) on day 1 and Prednisone 100 mg for 5 days every 21 days) or six cycles of R-B: Rituximab 375 mg/m2 on day 1 and Bendamustine 90 mg/m2 on days 1 and 2 of the cycle every 28 days.
In order to ensure the population was homogeneous, patients diagnosed with FL grade 3B, patients who had not undergone baseline or reassessment 18FDG PET/CT after immunochemotherapy at our Institute, and patients for whom it was impossible to access the images or examine the radiomic parameters considered were excluded.Table 1 summarizes the characteristics of the evaluated patients.
The database included 150 patients with FL in the 60–80 age range, and 71 were excluded because they did not fulfil the inclusion criteria. Early-stage patients who had performed only locoregional radiotherapy or for whom treatment criteria were not matched were excluded from our study. Patients who had performed immunochemotherapy treatments other than the R-CHOP or R-B regimen were also excluded.
For each patient, PET/CT was performed at the beginning of immunochemotherapy treatment and one month after its completion. For each patient, we considered descriptive parameters such as age and sex and clinical criteria such as the date of diagnosis, histology, Ann Arbor stage, performance status according to the ECOG scale, weight, and height; from these we calculated FLIPI, response to the end of therapy, the date of progression (if present), and the date of last contact or death. Finally, from the radiomic parameters we calculated and measured BMD, SMI, VAT, SAT, SMD, and SMA at onset and after chemoimmunotherapy treatment.
Patient inclusion criteria included an age range of 60–80 years, a baseline 18FDG PET/CT scan suitable for radiomic analysis performed at the Department of Diagnostic Imaging Radiology of the Policlinico Tor Vergata, first-line treatment with six cycles R-CHOP: Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 (liposomal Doxorubicin 50 mg/m2 in R-COMP), Vincristine 1.4 mg/m2(for a maximum of 2 mg total dose) on day 1 and Prednisone 100 mg for 5 days every 21 days) or six cycles of R-B: Rituximab 375 mg/m2 on day 1 and Bendamustine 90 mg/m2 on days 1 and 2 of the cycle every 28 days.
In order to ensure the population was homogeneous, patients diagnosed with FL grade 3B, patients who had not undergone baseline or reassessment 18FDG PET/CT after immunochemotherapy at our Institute, and patients for whom it was impossible to access the images or examine the radiomic parameters considered were excluded.
The database included 150 patients with FL in the 60–80 age range, and 71 were excluded because they did not fulfil the inclusion criteria. Early-stage patients who had performed only locoregional radiotherapy or for whom treatment criteria were not matched were excluded from our study. Patients who had performed immunochemotherapy treatments other than the R-CHOP or R-B regimen were also excluded.
For each patient, PET/CT was performed at the beginning of immunochemotherapy treatment and one month after its completion. For each patient, we considered descriptive parameters such as age and sex and clinical criteria such as the date of diagnosis, histology, Ann Arbor stage, performance status according to the ECOG scale, weight, and height; from these we calculated FLIPI, response to the end of therapy, the date of progression (if present), and the date of last contact or death. Finally, from the radiomic parameters we calculated and measured BMD, SMI, VAT, SAT, SMD, and SMA at onset and after chemoimmunotherapy treatment.
Free full text: Click here
